齐拉西酮联合米氮平对精神分裂症失匹配性负波电位的影响

The effect of ziprasidone combined with mirtazapine on mismatched negative wave potential in schizophrenia

目的探讨齐拉西酮联合米氮平对精神分裂症失匹配性负波(MMN)电位的影响。方法选取2018年10月至2019年10月就诊于赣州市第三人民医院的精神分裂症患者100例,采用随机数字表法分为对照组与研究组两组,各50例。对照组用齐拉西酮片治疗,研究组用齐拉西酮片联合米氮平片治疗,两组治疗8周。比较两组治疗8周的疗效和治疗前、治疗4周、8周的阳性与阴性症状量表(PANSS)评分、MMN潜伏期和波幅;比较两组治疗期间发生的不良反应。结果研究组总有效率较对照组高(P<0.05);两组治疗4周、治疗8周的PANSS总分低于治疗前,两组治疗8周的PANSS总分低于治疗4周,且研究组治疗4周、8周的PANSS总分低于对照组(P<0.05);两组治疗8周的MMN潜伏期较治疗前短,波幅较治疗前高,研究组MMN潜伏期较对照组短,波幅较对照组高(P<0.05);两组治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论齐拉西酮联合米氮平治疗精神分裂症患者可以提高治疗疗效,改善临床症状,缩短MMN潜伏期,提高波幅,改善患者认知功能,且无严重的不良反应。

Objective To investigate the effect of ziprasidone combined with mirtazapine on mismatched negative wave(MMN)potential in schizophrenia.Methods A total of 100 patients with schizophrenia who attended the Third People’s Hospital of Ganzhou from October 2018 to October 2019 were selected and divided into two groups by random number table method,with 50cases in each group.The control group was treated with ziprasidone tablets,and the study group was treated with mirtazapine tablets on the basis of the control group.The two groups were treated for 8 weeks.The efficacy of 8 weeks of treatment and the PANSS scores,MMN incubation period and amplitude before treatment,4 weeks and 8 weeks of treatment were compared between the two groups.The incidence of adverse reactions during the treatment period of the two groups was compared.Results The total effective rate of the study group was higher than that of the control group(P<0.05).The total PANSS scores of the two groups of treatment for 4 weeks and 8 weeks were lower than before treatment,and the total PANSS scores of the two groups of treatment for8 weeks were lower than that of 4 weeks,and the total PANSS scores of the study group for 4 weeks and 8 weeks were lower than those of the control group(P<0.05).The MMN incubation period of the two groups of treatment for 8 weeks was shorter than before treatment,and the amplitude was higher than before treatment.The MMN incubation period of the study group was shorter than that of the control group.The amplitude was higher than that of the control group(P<0.05);there was no statistically significant difference in the incidence of adverse reactions between the two groups during the treatment period(P>0.05).Conclusion Ziprasidone combined with mirtazapine in the treatment of patients with schizophrenia can improve the therapeutic effect,improve the clinical symptoms,shorten the incubation period of MMN,increase the amplitude,and improve the cognitive function of the patients without serious adverse reactions.